Literature DB >> 3145868

In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101.

A L Barry1, K E Aldridge, S D Allen, P C Fuchs, E H Gerlach, R N Jones, M A Pfaller.   

Abstract

Six geographically separate laboratories within the USA tested 6,198 bacterial isolates against FCE 22101 (a penem), imipenem (a carbapenem) and ceftazidime (a third-generation cephalosporin). Ninety-three percent of 2,749 Enterobacteriaceae were inhibited by FCE 22101, while 95% were susceptible to ceftazidime and 99% were susceptible to imipenem. FCE 22101 had little activity against Pseudomonas spp. but was active against most gram-positive pathogens, including enterococci. FCE 22101 MICs for standard quality control strains were defined as 0.5-2.0 micrograms/ml for Escherichia coli ATCC 25922, 2-8 micrograms/ml for Enterococcus faecalis ATCC 29212 and 0.06-0.25 microgram/ml for Staphylococcus aureus ATCC 29213.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145868     DOI: 10.1007/bf01975053

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  Susceptibility of anaerobic bacteria to FCE 22101.

Authors:  C E Nord; A Lindmark; I Person
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

2.  In-vitro activity of two new carbapenems FCE 22101 and CGP 31608 in comparison with imipenem.

Authors:  P Van der Auwera; F Ernst; P Grenier; Y Glupczynski; M Husson; J Klastersky
Journal:  J Antimicrob Chemother       Date:  1987-08       Impact factor: 5.790

3.  Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid.

Authors:  A L Barry; T L Gavan; R N Jones; L W Ayers; P C Fuchs; E H Gerlach; C Thornsberry
Journal:  Diagn Microbiol Infect Dis       Date:  1987-05       Impact factor: 2.803

4.  Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; G Danks
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

5.  The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  J Antimicrob Chemother       Date:  1985-09       Impact factor: 5.790

6.  Synthesis and biological properties of sodium (5R, 6S, 8R)-6 alpha-hydroxyethyl-2-carbamoyloxymethyl-2-penem-3-carboxylate (FCE 22101) and its orally absorbed esters FCE 22553 and FCE 22891.

Authors:  G Franceschi; M Foglio; M Alpegiani; C Battistini; A Bedeschi; E Perrone; F Zarini; F Arcamone; C Della Bruna; A Sanfilippo
Journal:  J Antibiot (Tokyo)       Date:  1983-07       Impact factor: 2.649

  6 in total
  2 in total

1.  Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa.

Authors:  Kiyomi Okamoto; Naomasa Gotoh; Takeshi Nishino
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

2.  Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay.

Authors:  K Okamoto; N Gotoh; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.